Ligand id: 8091

Name: reslizumab

1. Bodmer MW, Athwal DS, Emtage JS. (1999)
Interleukin-5 specific recombinant antibodies.
Patent number: US5998586. Assignee: Celltech Therapeutics, Limited. Priority date: 17/06/1994. Publication date: 07/12/1999.
2. Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. (2016)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Chest, 150 (4): 799-810. [PMID:27018175]
3. Shen HH, Ochkur SI, McGarry MP, Crosby JR, Hines EM, Borchers MT, Wang H, Biechelle TL, O'Neill KR, Ansay TL et al.. (2003)
A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse.
J. Immunol., 170 (6): 3296-305. [PMID:12626589]
4. Walsh GM. (2009)
Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions.
Curr. Opin. Mol. Ther., 11 (3): 329-36. [PMID:19479666]